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Background: Our study aimed to assess the safety and protective effect of maternal influenza vaccination on
pregnancy and birth outcomes.
Methods: The study population comprised 1253 healthy nulliparous pregnant women in South Australia
between 2015 and 2018. Participants were followed prospectively, with vaccination status (confirmed by
medical records), pregnancy, and birth outcome data collected by midwives. Adjusted relative risks (aRRs)
and adjusted hazard ratios (aHRs) were estimated accounting for time-varying vaccine exposure and tempo-
ral nature of each outcome.
Findings: Maternal influenza vaccination (48%, 603 of 1253) reduced the risk for pre-delivery hospitalisation
with influenza like illness (aHR 061; 95% CI 039, 097). Maternal influenza vaccination was not associated
with spontaneous abortion (aHR 042, 95% CI 012, 145), chorioamnionitis (aRR 078, 95% CI, 032, 188),
gestational hypertension (aHR 078, 95% CI 047, 129), pre-eclampsia (aHR 0.84, 95% CI 054, 127), gesta-
tional diabetes (aHR 116, 95% CI 082, 166) nor preterm birth (aHR 094, 95% CI 059, 149). No associa-
tions between antenatal influenza vaccination and congenital anomalies, admission to the neonatal care
unit, low Apgar scores, and mechanical ventilation were observed. Results were not materially changed after
adjustment for pertussis vaccination. We observed a protective effect of maternal influenza vaccination on
low birth weight (aHR 046, 95% CI 023, 094) and a marginal protective effect on small for gestational age
births (aHR 065, 95% CI 040, 104) during periods of high influenza activity.
Interpretation: These results support the safety of maternal influenza vaccination and suggest a protective
effect in reducing the rates of low birthweight and small for gestational age births.
Funding: There was no funding for this study.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)nology Research Trials Unit,
, North Adelaide 5006, South
. Marshall).
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Pregnant women are vulnerable to serious complications from
influenza including preterm labour, pneumonia, hospitalisation and
death, particularly during seasonal and pandemic influenza out-
breaks [1,2]. Newborns whose mothers had influenza during preg-
nancy are also at increased risk of adverse outcomes such as pretermbirth and low birthweight [3,4]. Maternal influenza vaccination pro-
tects mothers against influenza infection and their offspring by trans-
placental antibody transfer from mother to foetus conferring passive
immunity until the first influenza vaccination from age six months
[5,6]. Influenza vaccination during pregnancy might also reduce the
risk of low birthweight, preterm birth, and stillbirth but evidence
concerning these birth outcomes is conflicting [713]. Despite rec-
ommendations for maternal influenza vaccination, uptake during
pregnancy remains suboptimal globally [14].
A major challenge for achieving high uptake of influenza vaccina-
tion during pregnancy relates to relatively limited published evi-
dence of vaccine safety for pregnant women and their foetus [812].
Research in context panel
Evidence before this study
We searched PubMed for English language studies published
until March 31, 2020, with no start date restriction, with the
terms “influenza”, “influenza vaccine”, “maternal influenza vac-
cination”, maternal influenza immunisation”, “humans” and
“pregnancy”. The World Health Organization (WHO) considers
pregnant women as a priority group for seasonal inactivated
influenza vaccination due to their vulnerability to influenza
infection and its resulting morbidities. Previous studies have
shown that inactivated influenza vaccine during pregnancy is
safe and provides passive antibodies to the infant, as well as
clinical protection for both mother and infant < 6 months of
age against influenza infections and influenza-related hospital-
isations. Despite the recommendation of maternal influenza
vaccination from immunisation advisory groups internationally
including WHO, it has not been implemented in most low-
resource countries, and even in high income countries where it
is incorporated into standard antenatal care, vaccination uptake
is often suboptimal. While the body of literature regarding the
safety of influenza vaccination during pregnancy is mounting,
there are relatively few prospectively designed or clinical trials
that include pregnant women. In high income countries where
maternal influenza vaccination is recommended, prospectively
designed studies with advanced statistical approaches are likely
to be the only way to comprehensively assess the safety of
influenza immunisation during pregnancy and its important
potential protective effects in reducing low birth weight, small
for gestational age birth and preterm birth, for which evidence
is conflicting.
Added value of this study
This prospective cohort of healthy pregnant women, with con-
firmed vaccination status and accurate pregnancy and infant
outcome data used robust nuanced time-to-event analyses. The
study showed that influenza vaccination during pregnancy is not
associated with adverse pregnancy, foetal or birth outcomes.
This study also presents evidence that inactivated influenza vac-
cination decreases the risk of pre-delivery hospitalisation with
maternal influenza-like illness by 39% and reduces the risk of
low birthweight and small for gestational age births during peri-
ods of high influenza activity.
Implications of all the available evidence
These findings provide further reassurance to women and
health care providers about the safety of inactivated influenza
vaccination during pregnancy. Importantly, our results provide
evidence in support of maternal influenza vaccination reducing
low birth weight and small for gestational age births during
periods of widespread influenza activity. These findings need to
be replicated in other countries as it is plausible that the impact
of maternal influenza vaccine on these birth outcomes may
vary with the underlying local influenza epidemiology and
demographic characteristics. Our findings could be pivotal for
countries weighing the additional benefits of implementing
maternal influenza immunisation programs. This may be par-
ticularly important for low income countries where the rates of
low birthweight and small for gestational age births are very
high, and known to be strong risk factors for neonatal and early
childhood morbidity and in which health systems have poor
capacity to mitigate short and long-term effects.
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indicated that access issues and safety concerns are major barriers to
uptake [15]. An inflammatory response from infection during preg-
nancy has been shown to increase the risk of foetal injury [16] but no
evidence exists that an inflammatory response from a vaccine carries
a similar risk. A robust assessment of the safety of influenza vaccina-
tion during pregnancy is critical due to population-wide rollouts of
vaccines for this group. A number of systematic reviews have
reported pregnancy and birth safety outcomes following influenza
vaccination in pregnancy [813].
Most observational research into vaccine safety and efficacy
during pregnancy has been retrospective, due to the relatively
cheaper cost, fewer ethical concerns, and difficulty in recruiting
pregnant women to randomized controlled trials (RCTs). Whilst
providing timely reporting, this approach has limitations. In most
retrospective studies, authors have been unable to establish if a
pregnancy complication preceded vaccination nor account for the
time-dependant nature of exposure to vaccination during preg-
nancy. In countries where maternal influenza vaccination is rec-
ommended, prospectively designed studies are likely to be the
only way to accurately determine the true risk or potential bene-
fits of maternal vaccination beyond prevention of influenza for
pregnant women and their infants. Our study aimed to prospec-
tively assess maternal and birth outcomes following inactivated
influenza vaccination during pregnancy, while also taking into
account the most comprehensive set of potential confounding
variables considered to date.
2. Methods
2.1. Study design and participants
The current study draws on data collected as part of a prospective
cohort study (STOP), which aims to develop screening tests to iden-
tify adverse pregnancy outcomes. Healthy nulliparous women were
recruited in pregnancy at two major maternity hospitals, the Lyell
McEwin Hospital, the tertiary hospital serving the low socio-eco-
nomic community in Adelaide’s Northern suburbs and the Women’s
and Children’s Hospital, the primary tertiary maternity hospital for
complex care, accounting for around 50% of the 16,000 annual births
in metropolitan Adelaide, South Australia. Between March 2015 and
December 2017, nulliparous women with a singleton pregnancy
attending their first antenatal clinic between 9 + 0 and 16+0 weeks’
gestation were enroled. Women were excluded if they were consid-
ered already at high risk of pregnancy complications at screening (i.e.
experienced three or more previous miscarriages or with pre-existing
hypertension or diabetes). Participants were followed prospectively,
with vaccination, pregnancy, and birth outcome data collected by
research midwives. Written informed consent was obtained from all
participants included in the STOP study. The original STOP study pro-
tocol was approved by the Human Research Ethics Committee of the
Women’s and Children’s Hospital Adelaide Australia (HREC/14/
WCHN/90), registered at Australian New Zealand Clinical Trials Regis-
try, ACTRN12614000985684.
2.2. Exposure
The exposure of interest was trivalent inactivated influenza vacci-
nation during pregnancy, defined as a vaccine received between the
first day (date) of the last menstrual period and the end of pregnancy.
A research midwife interviewed and collected maternal vaccination
status of the women during their first study visit at 916 weeks’ ges-
tation and during their second study visit interview at 3236 weeks’
gestation. Vaccination date and gestation of administration were
recorded. Following delivery, a research midwife interviewed the
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cal case notes and Pregnancy-Hand-Held-Record to confirm the
reported vaccination status. Pregnancy-Hand-Held-Records are the
main medical record of pregnancy care in South Australia and are
reviewed and updated at antenatal appointments.
2.3. Outcomes
Pregnancy outcomes assessed were pre-delivery admission due to
influenza-like illness, spontaneous abortion after inclusion in the
STOP study, gestational diabetes, gestational hypertension, pre-
eclampsia, severe pre-eclampsia, chorioamnionitis, premature rup-
ture of membranes, spontaneous preterm birth, preterm birth and
stillbirth. Birth outcomes included congenital anomalies, small for
gestational age (SGA), low birthweight (< 2500 g) (LBW), low birth-
weight at term ( 37 weeks’ gestation), Apgar scores at 1 and 5 min,
neonatal care unit admissions, respiratory distress and mechanical
ventilation.
Pregnancy and birth complications were diagnosed using the
Brighton Collaboration consensus list of terms, and international
guidelines. Gestational hypertension was defined as (peripheral)
hypertension [systolic BP (SBP)  140 mmHg or diastolic BP (DBP) 
90 mmHg] after 20 weeks of gestation in previously normotensive
women. Pre-eclampsia was defined as gestational hypertension with
proteinuria (24 h urinary protein  300 mg or spot urine protein: cre-
atinine ratio  30 mg/mmol creatinine or urine dipstick protein  2+)
or any multi-organ complication of pre-eclampsia. Severe pre-
eclampsia was defined as pre-eclampsia with one or more of the fol-
lowing clinical features: BP of  160/110 mmHg or hypertension
requiring intravenous therapy with an antihypertensive agent or
magnesium sulphate after 20 weeks of gestation. Preterm birth was
defined as any birth before 37 and after 20 completed weeks of gesta-
tion. SGA was defined as neonates with a birthweight below the
<10th percentile customized for maternal factors such as maternal
height, booking weight, ethnicity and gestational age at delivery. The
estimated date of delivery was calculated from a certain last men-
strual period (LMP) date and was only adjusted if either (1) a scan
performed at < 16 weeks of gestation found a difference of 7 days
between the scan gestation and that calculated by the LMP or (2) on
20-week scan a difference of  10 days was found between the scan
gestation and that calculated from the LMP. If the LMP date was
uncertain, then scan dates were used to calculate the estimated date
of delivery.
2.4. Covariates
During the first study visit at 916 weeks’ gestation, informa-
tion was obtained regarding baseline socio-demographic, lifestyle
and clinical characteristics such as age, ethnicity, level of educa-
tion, household income, employment, exercise, smoking, supple-
ment use, intake of alcohol and recreational drugs, medical and
obstetric history, and complications during the current pregnancy.
Participating women also completed the Perceived Stress Scale
(PSS-10), to assess perceived stress levels in the past month, the
short form of the Spielberger StateTrait Anxiety Inventory
(STAI), assessing current anxiety symptoms, and the Edinburgh
Postnatal Depression Scale (EPDS), assessing depressive symp-
toms during pregnancy.
2.5. Statistical methods
Demographic, lifestyle and clinical characteristics of participants
were summarized descriptively, by influenza vaccination exposure
during pregnancy. Continuous variables were summarized as mean
with standard deviation (SD) or median with interquartile range
(IQR), as appropriate, while counts and percentages were used tosummarize categorical variables. To investigate if there was an
association between influenza vaccination status and each of the
outcome variables, we initially conducted independent samples t-
tests or Mann-Whitney U tests, as appropriate, for continuous
variables and chi-square tests of association for binary and cate-
gorical variables.
The timing for vaccination exposures and time at risk windows
were calculated for each time sensitive pregnancy and birth outcome
accounting for the temporal nature of each outcome of interest. For
example, women were at risk for preterm birth from 20 weeks until
36+6 weeks of gestation. Cox proportional-hazards models with gesta-
tional age in weeks as the underlying time metric were used to derive
hazard ratios (HRs) that compared the hazard rates for time-sensitive
outcomes such as spontaneous abortion or preterm birth between vac-
cinated and unvaccinated women. Vaccination status was treated as a
time-varying exposure in these models, in that each vaccinated wom-
an’s pregnancy was decomposed into an unvaccinated exposure
period and a vaccinated exposure period. In sensitivity analyses, we
estimated HRs and adjusted HRs of time-dependant pregnancy or birth
outcomes by trimester of influenza vaccination during pregnancy. To
assess the impact of the intensity of influenza activity on the associa-
tion between maternal influenza vaccination and key birth outcomes,
we also stratified analyses by the level of influenza activity at time of
delivery using the South Australian Influenza Surveillance Report [17]
based on the percentage of laboratory confirmed influenza during the
study period 20152018. We identified high activity periods as having
rates of laboratory confirmed influenza of at least 10% for at least 3 of
4 consecutive weeks. Low influenza activity period was defined as the
first week during which the positive rate was lower than 10% and
remained at that level for at least four consecutive weeks. On this basis,
“high influenza activity” periods were identified for 01 June 31 Octo-
ber 2015, 01 July  31 December 2016, 01 June  30 November 2017
and 31 August  31 October 2018. The delivery months of the vacci-
nated women were classified into “high” and “low” influenza activity
to compare key birth outcomes of infants born to vaccinated mothers
during high/low influenza activity with births occurring at any time to
unvaccinated women.
We used log-binomial models to estimate risk ratios (RR) and
adjusted risk ratios (aRR) comparing risk of late onset or early post-
partum adverse pregnancy outcomes and adverse birth outcomes
including congenital anomalies, low Apgar score, admission to neo-
natal unit, respiratory distress syndrome and mechanical ventilation
in infants of vaccinated and unvaccinated mothers. Finally, we used a
multivariable linear regression model to predict the difference in
mean gestational age at delivery and mean birthweight by vaccina-
tion status. For all multivariable (i.e. adjusted) models, annual house-
hold income, level of education, ethnicity, maternal health risk
factors (age, gravidity, alcohol intake, recreational drug use, smoking,
pre-pregnancy body mass index (BMI)), use of micronutrient supple-
ments, asthma and current psychological states were amongst the
variables selected as potential confounders based on evidence in the
literature [811] guided by directed acyclic graphs. Additional sensi-
tivity analyses were conducted in all multivariable models to evalu-
ate whether the effects of maternal influenza vaccination on
pregnancy and birth outcomes were maintained after adjustment for
pertussis vaccination in third trimester. As pertussis vaccination was
also recommended in pregnancy from 28 to 32 weeks’ gestation in
Australia, in our linear regression analyses, we restricted the cohort
to women whose pregnancies reached at least 32 weeks’ gestation to
allow for all women to have had the opportunity to receive the per-
tussis vaccine. Missing covariate values are reported in the baseline
table where relevant. The amount of missing data is minimal ranging
between 01% (estimated season of delivery data) to 23% (STAI
data), and therefore all available data were used in the analyses of all
pre-specified outcomes. For all analyses, a p value< 005 was consid-
ered statistically significant. Data were recorded in a REDCap [18, 19]
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Stata version 15 (Stata Corp, College Station, Texas, USA).
Role of Funding Source: Not applicable
3. Results
Of 1364 pregnant women enroled, 12 withdrew access to their
medical records, three had no medical case notes and three were lost
to follow up or delivered elsewhere (n = 10); all 28 were excluded
from our final analyses. So as not to confound any observed associa-
tions, we excluded 83 women who had influenza vaccination prior to
pregnancy. Our final cohort consisted of 1253 women (Fig. 1). Key
variables of interest did not differ between women included and
excluded from our study (supplementary material p 1). At recruit-
ment, mean maternal age of nulliparous women was 259 years (SD
50) (range: 1545 years) and median gestational age was 114
weeks (IQR 91128) with 822% (1031 of 1253) presenting for
their first antenatal care visit in the first trimester of pregnancy.
The overall uptake of influenza vaccination was 481% (603 of
1253); of the vaccinated women, 240% (n = 145) were vaccinated in
first trimester, 202% (n = 122) in second trimester, and 557%
(n = 336) in third trimester. Both influenza and pertussis vaccinations
occurred in 555 of 1253 (442%) pregnancies. Unvaccinated women
were more likely to be younger, Aboriginal and/or Torres Strait
Islander, in lowest household income group, smoke cigarettes, use
illicit drugs, physically inactive, have lower educational attainment
and less likely to take micronutrient supplements pre-conception or
during pregnancy, and give birth during Autumn compared with vac-
cinated pregnant women (Table 1).
3.1. Pregnancy outcomes
Of the 1253 women, 34 (27) had spontaneous abortions < 20
weeks’ gestation, seven had terminations (05%), six had stillbirthsEnrolled to study at 9–16 weeks’ 
gestation (n=1373)
Eligible women (n=1364)








Final eligible women with vaccination statu
during pregnancy (n=1253)
Fig. 1. Participants(04%), and 1201 (958%) delivered a live infant (five missing values).
The mean gestational age at delivery was 392 weeks (SD 20 weeks).
Overall, 95 of 1253 (75%) women were admitted to hospital due to
influenza like illness during pregnancy; mostly in the third (93 of 95)
trimesters of pregnancy. The time-dependant Cox proportional haz-
ards regression model shows that women vaccinated at any time
during pregnancy had a significant lower risk of pre-delivery hospi-
talisation with influenza like illness compared to unvaccinated
women (aHR 061; 95% CI 039, 097) (Table 2). After accounting for
the assumption that immunologic protection after influenza vaccina-
tion requires 2 weeks for full effect, the estimated aHR remained
unchanged (supplementary material p 2). The observed protective
effect of maternal influenza vaccination in reducing hospitalisation
due to influenza like illness was stronger for those vaccinated in sec-
ond trimester (aHR 009; 95% CI 001, 071) and those who delivered
during periods of high influenza activity (aHR 051; 95% CI 027,
095) (Table 3).
There was no association with spontaneous abortion for women
who were vaccinated for influenza prior to 20 weeks’ gestation (aHR
042, 95% CI 012, 145) (Table 2). Our Cox model shows that influ-
enza vaccination during pregnancy was not associated with maternal
hypertensive disorders including gestational hypertension (aHR
078, 95% CI 047, 129), pre-eclampsia (aHR 084, 95% CI 054,
127) or severe pre-eclampsia (aHR 065, 95% CI 026, 164)
(Table 2). Additional adjustment for maternal pertussis vaccination
as a time-varying covariate yielded similar results for hypertensive
disorders (supplementary material p 2). In the log-binomial models,
there was no association between risk of chorioamnionitis and influ-
enza vaccination during pregnancy (aRR 078, 95% CI, 032, 188)
(Table 4).
After adjusting for covariates, women vaccinated for influenza
during pregnancy had on average 18 days longer gestation at deliv-
ery than unvaccinated women (Table 2). Restricting the analysis to
pregnancies reaching at least 32 weeks’ gestation followed byExcluded pregnancies (n=9)
Multiple gestation (n=8)
High risk pregnancy (n=1)
Excluded influenza vaccine uptake - in 






Missing data on influenza vaccination 
status or pregnancy outcome (n=28)
Withdrawn access to medical record (n=12)
No medical record (n=3)
Lost to follow up (n=3)
Delivered elsewhere/incomplete data on 
pregnancy and birth outcomes (n=10)
flow diagram.
Table 1
Maternal characteristics of vaccinated and unvaccinated pregnant women who delivered at two obstetric hospitals in South Australia, 2015 to
2018 (N = 1253).
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Illicit drug use during 1st trimester/pre-pregnancy 29 (48) 46 (70)
Multivitamin and mineral supplements use












Moderate exercise during 1st trimester/pre-pregnancy












Gravidity >1 165 (273) 185 (284)














Psychological measures at 916 weeks’ gestation
Edinburgh Perinatal Depression Scale (EPDS) scores, mean (SD)
State and trait anxiety (STAI) scores, mean (SD)


















Gestational week of vaccine administration, mean (SD) 230 § 105 NA
Received pertussis vaccination during pregnancy 555 (920) 398 (612)
















Data are mean (SD) or n (%). SD= standard deviations. AUD=Australian dollars. BMI=body-mass-index.
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ferences in gestational age at birth between unvaccinated and vacci-
nated mothers were negligible (supplementary material p 2). Overall,
73% (89 of 1207) of pregnancies resulted in preterm birth. There
was no difference in stillbirth between vaccinated (n = 3) and unvac-
cinated women (n = 3). Our time-dependant analysis showed no
association between influenza vaccination through to 37 weeks’ ges-
tation and preterm birth (aHR 094, 95% CI 059, 149), preterm pre-
mature rupture of the membranes (aHR 085, 95% CI 044, 163),
and spontaneous preterm birth (aHR 074, 95% CI 041, 133)(Table 2). Maternal influenza vaccination showed a modest reduction
in the hazard of spontaneous preterm birth during periods of lower
influenza virus circulation but the confidence intervals were wide
and included one (aHR 052, 95% CI 024, 113) (supplementary
material p 3).
3.2. Birth outcomes
Maternal influenza vaccination was protective against delivering
LBW term infants in our Cox proportional hazard regression analyses
Table 2
Crude and adjusted hazard ratios for time-based pregnancy and birth outcomes by maternal influenza vaccination status at two obstetric hospitals in South Australia 20152018.
Variables Total Unvaccinated N (%) Vaccinated N (%) Crude HR* (95% CI) p-value Adjusted y aHR (95% CI) p-value
Pre-delivery hospitalisation due
to influenza like illness z
95/1253 (75) 60/650 (92) 35/603 (58) 058 (037, 091) 0018 061 (039, 097) 0038
Spontaneous abortion x 34/1253 (27) 31/650 (47) 3/603 (05) 066 (020, 219) 0507 042 (012, 145) 0171
Gestational hypertension || 81/1205 (67) 41/606 (67) 40/599 (66) 080 (049, 131) 0391 078 (047, 129) 0343
Pre-eclampsia || 111/1205 (92) 58/606 (95) 53/599 (88) 085 (058, 126) 0445 084 (054, 127) 0417
Severe pre-eclampsia || 28/1204 (23) 14/606 (23) 14 /598 (23) 086 (037, 196) 0725 065 (026, 164) 0368
Gestational diabetes { 190/1207 (157) 85/608 (139) 105/599 (175) 133 (095, 184) 0088 116 (082, 166) 0383
Preterm premature rupture of
the membranes **
47/1207 (38) 27/608 (44) 20/599 (33) 082 (043, 156) 0561 085 (044, 163) 0634
Preterm birth ** 89/1207 (73) 49/608 (80) 40/599 (66) 094 (060, 147) 0802 094 (059, 149) 0817
Spontaneous preterm birth ** 59/1207 (48) 36/608(59) 23/599 (38) 071 (040, 126) 0253 074 (041, 133) 0323
LBW (<2500 g) yy 80/1205 (66) 49/606 (80) 31/599 (51) 070 (042, 114) 0158 071 (043, 119) 0202
LBW at term (<2500 g)yy, zz 29/1116 (26) 20/557 (35) 9 /559 (16) 043 (018, 099) 0048 038 (016, 089) 0027







Mean birth weight yy, g (95% CI) 33349 § 557 33018 § 610 33684 § 498 637 (009, 1270) 0050 588 (- 42, 1217) 0067
Mean gestational age at delivery,
weeks (95% CI)
392 § 20 391 § 23 394 § 16 026 (004, 049) 0019 027 (004, 049) 0019
CI=confidence interval. HR=hazard ratios. LBW=low birthweight. SGA=small for gestational age.
* HR results compared outcome variable in vaccinated group to reference (unvaccinated).
y Adjustments were made for maternal age, race/ethnicity, education, household income, gravidity, intake of alcohol and recreational drugs, smoking, pre-pregnancy body mass
index (continuous), use of multivitamin supplements, Edinburgh Postnatal. Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Perceived Stress Scale (PSS-10), phys-
ical activity, infertility treatment, asthma and estimated season of delivery.
z Women admitted to hospital with influenza/ respiratory tract infection were censored at their admission date.
x The time metric for spontaneous abortion analysis was the first week of gestation up to the event (week of last available pregnancy data or week 20 of gestation; whichever
occurred first).
|| For hypertensive disorders analysis, women who were vaccinated at or after the gestational age at diagnosis ( 20 weeks' gestation) and pregnancies ending prior to 20 weeks
of gestation were censored.
{ Women who were vaccinated at or after the gestational age at diagnosis of gestational diabetes mellitus (median gestational age at screening was 278 (IQR, 26529) weeks)
were censored.
** Women vaccinated at 37 weeks’ or later were censored because they were no longer at risk of preterm birth.
yy Additionally adjusted for infant's sex.
zz Low birthweight at term (<2500 g and  37 completed weeks’ gestation at birth).
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ing additional adjustment for maternal pertussis vaccination (aHR
038, 95% CI 015, 094) (supplementary material p 2). An even
greater protective effect of influenza vaccination against delivering a
LBW infant at term (aHR 020, 95% CI 004, 087) and LBW in either
preterm or term infants (aHR 046, 95% CI 023, 094) was observed
during periods of high influenza activity (Table 3). There was no evi-
dence of increased risk of LBW associated with receipt of inactivated
influenza vaccine during any trimester of pregnancy (Table 3). First
trimester influenza vaccination had no effect on risk of congenital
anomalies (aRR 033, 95% CI 004, 273) (Table 4). Overall, 510
(422%) of 1207 infants were born during high influenza activity
across three Australian influenza seasons 20152018. The infants
born to vaccinated mothers were estimated to be 59 g heavier than
infants born to unvaccinated mothers (588 g, 95% CI 42 g,
1217 g) but the confidence intervals were wide and included zero
(Table 2). This association was attenuated (183 g, 95% CI  422 g,
790 g) after adjustment for maternal pertussis vaccination (supple-
mentary material p 2).
Our study found no increased risk for SGA delivery after influenza
vaccination during pregnancy (aHR 084, 95% CI 058, 120) (Table 2).
Maternal influenza vaccination was associated with a marginal
reduction in risk of SGA births during periods of high influenza activ-
ity (aHR 065, 95% CI 040, 104). Influenza vaccination in third tri-
mester was associated with a 39% reduction in risk of SGA birth
regardless of the level of influenza activity (aHR 061, 95% CI 038,
098) (Table 3). However, these protective effects on SGA were
slightly attenuated after adjustment for pertussis vaccination (sup-
plementary material p 3). There was no association between mater-
nal influenza vaccination and adverse infant outcomes including low
Apgar scores at 1 and 5 min, admission to the neonatal care unit,
mechanical ventilation, and respiratory distress syndrome (Table 4).4. Discussion
In robust nuanced analyses that account for timing of maternal
influenza vaccination and the time risk of adverse pregnancy out-
comes, we show maternal influenza vaccination is safe in a prospec-
tive cohort of healthy pregnant women, with confirmed vaccination
history and accurate, pregnancy and infant outcome data. There was
no evidence of associations between influenza vaccination adminis-
tered at any time in pregnancy and adverse pregnancy or foetal out-
comes including spontaneous abortion, congenital anomalies,
shortened gestation, gestational diabetes, chorioamnionitis or gesta-
tional hypertensive disorders, consistent with the literature [812].
In addition to reassuring safety of maternal influenza vaccination,
our study found influenza vaccination during pregnancy reduced a
pregnant woman's risk of pre-delivery hospitalisation with influenza
like illness by around 39%. This protective effect was most pro-
nounced for those women who delivered during periods of high
influenza activity, consistent with previous studies [20, 21]. Across
the three influenza seasons 20152018 in South Australia, influenza
A (H3N2) was the dominant circulating virus followed by influenza B
[17].
In contrast to our findings, a recent Bayesian meta-analysis of 28
cohort studies showed maternal influenza vaccination protects
against preterm birth [13]. However, the pooled summary estimates
[13] did not find any association when the preterm birth analysis
included 2 randomized placebo-controlled studies (RCTs) and 2 case-
control studies. The two RCTs [22, 23] investigating maternal influ-
enza vaccine efficacy and safety in South Africa and Nepal, respec-
tively, found that vaccination was not associated with preterm birth.
However, the RCT in Nepal showed a reduction of LBW [23] and
another RCT [7] conducted in Bangladesh demonstrated a reduction
of SGA amongst a subset of infants born during peak influenza
Table 3
Crude and adjusted hazard ratios for pre-delivery hospitalisation due to influenza like illness and key adverse birth outcomes stratified by trimester of influenza vaccination
and influenza activity.
Variables Unvaccinated N (%) Vaccinated N (%) Crude HR* (95% CI) p-value Adjustedy aHR (95% CI) p-value






































































































































































CI=confidence interval. HR=hazard ratios. LBW=low birthweight. SGA=small for gestational age.
* HR results compared outcome variable in vaccinated group to reference (unvaccinated).
y Adjustments were made for maternal age, race/ethnicity, education, household income, gravidity, intake of alcohol and recreational drugs, smoking, pre-pregnancy body
mass index (continuous), use of multivitamin supplements, Edinburgh Postnatal Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Perceived Stress Scale
(PSS-10), physical activity, infertility treatment, asthma and estimated season of delivery.
z Women vaccinated at 37 weeks’ or later were censored because they were no longer at risk of having a preterm birth.
x Additionally adjusted for infant's sex.
|| Low birthweight at term (<2500 g and  37 completed weeks’ gestation at birth).
{ Analysis by trimester of influenza vaccination was not performed because a small number of mothers who delivered LBW at term babies received the vaccine prior to
their third trimester (n = 1 during 1st trimester, n = 1 during 2nd trimester).
H. Mohammed et al. / EClinicalMedicine 26 (2020) 100522 7circulation to influenza-vaccinated women. We also found that vacci-
nated mothers were less likely to deliver LBW and SGA infants during
periods of high influenza activity. Decreased risk for LBW and SGATable 4
Pregnancy and birth outcomes following influenza vaccination in pregnancy at two obstetric
Pregnancy outcomes Total Unvaccinated N (%) Vaccinat
Chorioamnionitis and/or funisitis 25/1207 (20) 15/608 (24) 10/599 (
Postpartum haemorrhage 113/1205 (93) 62/606 (102) 51/599 (
Caesarean delivery (Vs Vaginal)y 349/1205 (289) 176/606 (290) 173/599
Birth outcomes
Congenital anomaliesz 23/1207 (19) 21/1066 (18) 2/141 (1
Low Apgar at 1 min (<7) 151/1201 (125) 72/603 (119) 79/598 (
Low Apgar at 5-min (<7) 31/1203 (25) 16/604 (26) 15/599 (
Admitted to Neonatal unitx 282/1207 (233) 140/608 (230) 142/599
Respiratory distress syndrome 14/1207 (11) 10/608 (16) 4/599 (0
Mechanical ventilation 51/1207 (42) 30/608 (49) 21/599 (
* Pregnancy outcomes were adjusted for maternal age, ethnicity, total years of full time e
ing, pre-pregnancy body mass index (continuous), use of multivitamin supplements, Edinb
ceived Stress Scale (PSS-10), physical activity, infertility treatment, asthma and estimated sea
y Poisson regression model was used because the log binomial model failed to converge.
z For congenital anomalies analysis, the exposure time window comprised the first trimes
x Reasons for admission: Preterm, Respiratory distress Infection, Feeding problem, Hypog
and Cyanosis.during peak influenza season amongst vaccinated mothers could be
attributed to decreased risk of influenza infection during pregnancy
following maternal influenza vaccination. Differing from our studyhospitals in South Australia 20152018.
ed N (%) Risk Ratios RR (95% CI) p-value Adjusted* aRR (95% CI) p-value
16) 065 (028, 149) 0316 078 (032, 188) 0581
85) 079 (055, 114) 0215 072 (049, 106) 0099
(288) 101 (093, 108) 0758 091 (075, 109) 0326
4) 031 (004, 233) 0256 033 (004, 273) 0311
132) 113 (083, 153) 0433 111 (081, 152) 0490
25) 093 (044, 197) 0874 084 (039, 181) 0670
(237) 098 (080, 122) 0780 104 (084, 128) 0693
6) 040 (012, 126) 0120 046 (014, 152) 0208
35) 072 (041, 126) 0258 074 (042, 131) 0313
ducation, household income, gravidity, intake of alcohol and recreational drugs, smok-
urgh Postnatal Depression Scale (EPDS), The State-Trait Anxiety Inventory (STAI), Per-
son of delivery Birth outcomes were additionally adjusted for infant's sex.
ter and women vaccinated after first trimester were classified as unvaccinated.
lycaemia, Drug withdrawal, SGA, Birth asphyxia, congenital abnormality, Phototherapy
8 H. Mohammed et al. / EClinicalMedicine 26 (2020) 100522findings, a secondary analysis of the RCT in Nepal [24], which was the
only trial powered to detect difference in birth weight has found that
maternal influenza vaccination significantly increased mean birth-
weight by 42 g. Birth weight is an important indicator of an infant's
vulnerability to the risk of childhood illness and chances of survival
and the health burden of babies born SGA or LBW is very high in low
income countries [25]. Reduction of these adverse birth outcomes fol-
lowing maternal influenza vaccination would be an important
achievement, particularly in tropical regions, where influenza circu-
lates year-round.
Consistent with previous studies, [26, 27] we demonstrated that
newborns whose mothers were vaccinated for influenza in preg-
nancy were not more likely to experience any adverse outcomes,
including admission to the neonatal care unit, respiratory distress,
low Apgar scores nor need for mechanical ventilation at birth com-
pared with neonates born to unvaccinated women. A protective
effect of maternal influenza vaccination on preventing either influ-
enza or influenza-related complications in infants up to 6 months old
[28, 29] provides important additional evidence that women should
be offered influenza vaccination during pregnancy, irrespective of
time of year.
Our study has a number of strengths and some potential limita-
tions. The major strength is the prospective cohort design that
recruited a large number of nulliparous women with singleton preg-
nancies at low risk for obstetric complications at two major maternity
hospitals, reducing potential confounding by indication. Such bias
could have occurred if women with known comorbidities and/or
high-risk factors were more likely to receive the influenza vaccine
during pregnancy and have a higher baseline risk of adverse preg-
nancy outcomes than healthy women leading to an underestimation
of vaccine safety. The opposite effect (i.e. an overestimate of the size
of the protective effect of maternal vaccination) due to a ‘healthy vac-
cinee bias’ could also have occurred. Vaccinated women in our study
were more likely to engage in healthy lifestyles i.e. pregnancy micro-
nutrient supplementation, exercise regularly and were less likely to
smoke or use illicit drugs in pregnancy than unvaccinated women.
The analysis framework used herein adjusted for putative risk factors,
including psychosocial factors, to mitigate the impact of any ‘healthy
vaccinee bias’ on our findings.
Our use of Cox proportional-hazards models accounting for time-
varying vaccine exposure within pregnancy, minimized the introduc-
tion of immortal time bias in our data [30]. The potential for this bias
arises because the opportunity for vaccination increases the longer a
woman remains pregnant and free of adverse foetal outcomes. The
fact that the pregnancies were not followed from the beginning (i.e.
first day of the last menstrual period), causes downward bias in esti-
mation of spontaneous abortion. Such data are said to be left trun-
cated. Additionally, including follow-up time during which
pregnancies are no longer at risk of some adverse outcomes (e.g. ges-
tation after 37 weeks’ considered for preterm birth outcomes) can
lead to overestimation of any true benefits of maternal vaccination
but our analysis strategy minimized the risk of these biases occurring.
One potential limitation that we could not take into account is that
vaccine administered in non-traditional settings (i.e. pharmacist or
community or workplace-administered vaccination) might not be
recorded in women’s Pregnancy-Hand-Held-Records. Thus, uptake of
vaccination during pregnancy may have been underestimated. How-
ever, this is unlikely as women were interviewed by a research mid-
wife at several time points including post-delivery to confirm final
vaccination status. Another limitation in our study is the inability to
distinguish pre-delivery hospital admission due to laboratory-con-
firmed influenza infections from influenza-like illness. However,
these limitations are likely to have negligible effects on our study
findings.
Evidence from previous influenza pandemics, and seasonal influ-
enza demonstrates that pregnant women and their infants are athigh risk of severe influenza-related complications [1, 2]. Our robust
study analysis demonstrated that maternal influenza vaccination
reduced pregnant women's risk of pre-delivery hospitalisation with
influenza like illness. Furthermore, our study provides a unique pro-
spective assessment of the safety of an inactivated influenza vaccine
amongst pregnant women providing reassurance for health pro-
viders and pregnant women. Importantly, although numerous factors
may contribute, we show positive impacts on key birth outcomes
that inordinately occur in low-middle income countries with long
term consequences for offspring health and impacts on low capacity
health systems.
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